VNRX Stock Analysis: Buy, Sell, or Hold?
VNRX - VolitionRX Limited Common Stock
$1.34
-0.09 (-6.29%)
▼
5d:
-2.9%
30d:
-46.18%
90d:
+616.19%
BUY
HIGH Confidence
Analysis Updated: Jun 22, 2026 12:00 AM ET
Earnings: Aug 13, 2026
Get Alerted When VNRX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: VNRX shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
✅ BUY SIGNAL: VNRX shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
In-depth Analysis How we analyze
Valuation Analysis: VNRX is currently trading at $1.34, which is considered oversold relative to its 30-day fair value range of $1.43 to $2.66. From a valuation perspective, the stock is trading at a discount (Forward PE: -1.2) compared to its historical average (0.6). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, VNRX is in a strong uptrend. The price is currently testing key support at $1.30. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 6.3% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $16.97 (+1166.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, VNRX is in a strong uptrend. The price is currently testing key support at $1.30. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 6.3% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $16.97 (+1166.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.43 -
$2.66
Company Quality Score
47/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
79.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-6.3%)
- BULLISH: Trading 1166.1% below Wall St target ($16.97)
- BULLISH: Market expects only 0% annual growth - appears undervalued
Trading Range Analysis
30-Day Trading Range
$1.43 -
$2.66
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$1.30
Resistance Level
$3.12
Current Trend
Strong Uptrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.17
Wall Street Target
$16.97
(+1166.1%)
Revenue Growth (YoY)
299.8%
PE vs Historical
-1.2 vs 0.6
CHEAP
Share & Embed Analysis
Last updated: June 23, 2026 2:46 AM ET
Data refreshes hourly during market hours. Next update: 3:46 AM
Data refreshes hourly during market hours. Next update: 3:46 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is VNRX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SYK
Stryker Corporation |
BUY
32 analysts |
$387 | 61 BUY |
|
ABT
Abbott Laboratories |
STRONG BUY
27 analysts |
$117 | 59 HOLD |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$98 | 63 BUY |
|
EW
Edwards Lifesciences Corp |
HOLD
32 analysts |
$97 | 57 HOLD |
|
ZBH
Zimmer Biomet Holdings I… |
HOLD
29 analysts |
$99 | 61 BUY |
